A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

NCT00558636 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
91
Enrollment
INDUSTRY
Sponsor class

Stopped Terminated early when the results from Study NCT00300885 showed an overall lack of efficacy in NSCLC and increased mortality in subjects with squamous subtype.

Conditions

Interventions

Sponsor

Bayer